Recs

8

The World Is Saving Pfizer

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

It's a good thing Pfizer (NYSE: PFE  ) recently set up a division to address emerging markets. The company is going global whether it likes it or not.

Revenue for the third quarter was essentially flat year over year, but it tells a tale of two distinct geographic areas. In the U.S., sales decreased 15%, while international sales increased 13%. Thanks to the divergence, international sales now make up 59% of total revenue.

The loss of chemotherapy drug Camptosar to generic competition and allergy drug Zyrtec, transferred to Johnson & Johnson (NYSE: JNJ  ) as part of the consumer health-care division Pfizer sold, cost Pfizer more than half a billion dollars in revenue in the quarter, compared with last year.

Despite the woes that competitors Merck (NYSE: MRK  ) and Schering-Plough (NYSE: SGP  ) have had with their cholesterol-lowering drug, Vytorin, Pfizer doesn't seem to have been able to win over their patients: U.S. sales of Lipitor dropped 13% year over year. We'll have to wait until AstraZeneca (NYSE: AZN  ) reports next week to see if doctors have been favoring AstraZeneca's Crestor or have been putting their patients on one of the generic statins.

Where Pfizer is generating its cash matters so much because it's the cash flow and the dividend in particular that are holding up the stock price; earnings, which were up 7% per share on an adjusted basis, just don't matter that much. The dividend is paid in U.S. dollars, and, if Pfizer needs to move cash from places where it pays low taxes to the U.S., it's likely it would have to take a tax hit when it repatriates the cash. At this point the dividend seems sustainable, but we'll have to wait for the 10-Q report filed with the SEC to see the cash flow for this quarter.

The world may be holding up Pfizer at this point, but it won't be able to sustain things after Lipitor loses exclusivity at the end of 2011. Pfizer is going to have to get some of the 25 programs currently in phase 3 trials onto the market and make an acquisition or two with all that cash it has been hoarding.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Pfizer and Johnson & Johnson are Motley Fool Income Investor selections. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is an Inside Value pick, too, and the Fool owns shares of Pfizer. The Fool's disclosure policy is good around the globe.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 758831, ~/Articles/ArticleHandler.aspx, 5/24/2012 3:13:46 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 12,451.04 -45.11 -0.36%
S&P 500 1,312.29 -6.57 -0.50%
NASD 2,821.47 -28.65 -1.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2012 2:57 PM
PFE $22.04 Down -0.05 -0.23%
Pfizer, Inc. CAPS Rating: ****
MRK $37.34 Down +0.00 +0.00%
Merck & Co., Inc. CAPS Rating: ****
SGP $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****
AZN $41.02 Down -0.04 -0.10%
AstraZeneca plc (A… CAPS Rating: *****
JNJ $62.99 Up +0.33 +0.52%
Johnson & Johnson CAPS Rating: *****

Advertisement